KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharmaceuticals is showing strong promise as its recent acquisition by Chiesi Group for $27.00 per share in cash effectively establishes the near-term value realization for shareholders, representing a meaningful premium to recent trading levels and implying an equity value of approximately $1.9B. The proposed transaction is expected to close in 3Q26 subject to customary conditions where we don't foresee any reason why it would not meet the closing conditions or face any regulatory scrutiny. The company also has a strong product in Ekterly, a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema, with impressive sales of ~$49MM in less than 6 months since its FDA approval. However, there are risks to consider, including financing, commercialization, and third-party risks, but the company is actively seeking partnerships to address these challenges.

KalVista Pharmaceuticals is likely to face challenges in generating revenue in the short term due to a lack of significant milestones and collaboration partners. Additionally, the company may require additional capital to fund its operations and may not become profitable for some time. The company has had success in securing partnerships with companies in Japan and Canada, but the launch dates for these products are still a ways off, which may lead to a lack of near-term revenue generation.